Pharsight

Drugs that contain Zolpidem Tartrate

1. Edluar patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597281 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Apr, 2027

(3 years from now)

US9265720 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Feb, 2031

(6 years from now)

Market Authorisation Date: 13 March, 2009

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of EDLUAR before it's drug patent expiration?
More Information on Dosage

EDLUAR family patents

Family Patents

2. Intermezzo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7682628 PURDUE PHARMA Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
Feb, 2025

(10 months from now)

US8252809 PURDUE PHARMA Compositions for treating insomnia
Feb, 2025

(10 months from now)

US7658945 PURDUE PHARMA Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
Apr, 2027

(3 years from now)

US8242131 PURDUE PHARMA Methods of treating middle-of-the-night insomnia
Aug, 2029

(5 years from now)

Market Authorisation Date: 23 November, 2011

Treatment: Method for treating insomnia; Method of treating middle-of-the-night insomnia

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of INTERMEZZO before it's drug patent expiration?
More Information on Dosage

INTERMEZZO family patents

Family Patents

3. Zolpimist patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8236285 AYTU Buccal, polar and non-polar spray containing zolpidem
Aug, 2032

(8 years from now)

Market Authorisation Date: 19 December, 2008

Treatment: Treatment of transient insomnia

Dosage: SPRAY, METERED;ORAL

More Information on Dosage

ZOLPIMIST family patents

Family Patents